WASHINGTON — The United States firm Novavax on Sept. 8 announced that it has initiated an early stage process to evaluate the safety and immunogenicity of a combined flu Novavax’s seasonal influenza and Covid-19 vaccines. The trial, to be conducted in Australia, will enroll 640 healthy adults between the ages of 50 and 70 years and who have either been previously infected […]

The post Novavax Begins Early-stage Trial For Combined Influenza, Covid-19 Vaccines first appeared on The Florida Star | The Georgia Star.